CD274 and head and neck squamous cell carcinoma: However, increasing evidence suggests that expression of PD-L1 in both TCs and ICs may be predictive of response to PD-L1 inhibitors such as durvalumab, and findings from the current study confirm that both TC and IC PD-L1 expression have predictive value for efficacy outcomes in patients with R/M HNSCC.